According to a recent article in the Sun News, patients in Canada are filing a class action lawsuit against the manufacturer of a testosterone replacement therapy (TRT) drug. The drug in question is Delatestryl, which is a form of testosterone delivered by injection. TRT drugs can be delivered by injection, skin gels, transdermal patches, and pills.
This TRT class action lawsuit is asserting negligence under a failure to warn theory. As your Boston testosterone replacement therapy attorney can explain, one of the typical reasons for filing a lawsuit against a drug company is because the company failed to warn patients of dangerous side effects that were known to the company. This is also sometimes called a deceptive marketing lawsuit.
In the case discussed in this article, the plaintiffs are alleging that they suffered from adverse cardiovascular events and that the drug manufacturer failed to warn both doctors and patients that TRT drugs are known to cause heart attacks, stroke, and deep vein thrombosis (DVT), which can lead to the potentially fatal occurrence of a pulmonary embolism. This the medical term for a clot that forms in the veins of the legs (DVT) and travels through the circulatory system to the lungs, where it can cause a hole and internal bleeding.
Continue reading